Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Post by bligickaon Feb 07, 2021 6:20pm
192 Views
Post# 32497128

South Africa halts AstraZeneca vaccinations over variant dat

South Africa halts AstraZeneca vaccinations over variant datSouth Africa halts AstraZeneca vaccinations over variant data

A vial of the Oxford-AstraZeneca vaccine against COVID-19 at a hospital in Sofia, Feb. 7, 2021, prior to the start of vaccination.

VALENTINA PETROVA/THE ASSOCIATED PRESS

South Africa will suspend use of AstraZeneca’s COVID-19 shot in its vaccination program after data showed it gave minimal protection against mild to moderate infection caused by the country’s dominant coronavirus variant.

Health Minister Zweli Mkhize said on Sunday the government would await advice from scientists on how best to proceed, after disappointing results in a trial conducted by the University of the Witwatersrand.

The government had intended to roll the AstraZeneca shot out to health care workers soon, after receiving 1 million doses produced by the Serum Institute of India on Monday.

Instead, it will offer vaccines developed by Johnson & Johnson and Pfizer in the coming weeks while experts consider how the AstraZeneca shot can be deployed.

“What does that mean for our vaccination program which we said will start in February? The answer is it will proceed,” Mkhize told an online news briefing.

 

“From next week for the next four weeks we expect that there will be J&J vaccines, there will be Pfizer vaccines. So what will be available to the health workers will be those vaccines.”

“The AstraZeneca vaccine will remain with us … up until the scientists give us clear indications as to what we need to do,” he added.

<< Previous
Bullboard Posts
Next >>